PF562271 - Small Molecule (ID:10072-101)

HMS LINCS ID: 10072-101
Name: PF562271
Alternative Names: KIN001-205
LINCS ID: LSM-1072
PubChem CID: 11713159
ChEBI ID:
ChEMBL ID:
Molecular Mass: 507.13
InChi: InChI=1S/C21H20F3N7O3S/c1-31(35(2,33)34)19-12(4-3-7-25-19)10-26-18-15(21(22,23)24)11-27-20(30-18)28-14-5-6-16-13(8-14)9-17(32)29-16/h3-8,11H,9-10H2,1-2H3,(H,29,32)(H2,26,27,28,30)
InChi Key: MZDKLVOWGIOKTN-UHFFFAOYSA-N
SMILES: CN(C1=C(C=CC=N1)CNC2=NC(=NC=C2C(F)(F)F)NC3=CC4=C(C=C3)NC(=O)C4)S(=O)(=O)C
Relevant Citations:
Comments:
Date Publicly Available:
Most Recent Update: 2016-04-04

Target Affinity:

(see Study 20000)
Target Affinity Spectrum Value HUGO Gene Name
1
(Kd <100 nM)
AIM1, AURKB, CDK1, CDK2, CDK5, CDK7, CDK9, CLK4, FRK, GSK3A, ITK, JAK2, MAPK1, MARK4, MELK, NTRK2, PTK2, PTK2B, ROS1
2
(equivalent to 100 nM ≤ Kd < 1µM)
ALK, AURKA, AXL, BLK, CAMKK2, CHEK2, CLK2, FGFR1, FGFR3, FLG, FLT1, FLT3, FLT4, GSK3B, HIPK2, HIPK4, IGF1R, INSR, IRAK4, KDR, LCK, LRRK2, LTK, LYN, MAP3K10, MAP4K4, MAP4K5, MAPK10, MARK2, MARK3, MATK, MET, MINK1, MST1R, NTRK1, NTRK3, PAK4, PKN2, PLK4, PRKAA1, PRKACA, PRKCQ, PRKX, RET, RPS6KA3, SIK2, SLK, SRC, STK3, TAOK1, TYK2
3
(equivalent to 1µM ≤ Kd < 10 µM)
ABL1, ACVR1, AKT1, AKT2, BRSK1, BTK, CAMK1, CAMK1D, CAMK2A, CAMK2B, CAMK2D, CAMK2G, CDC42BPA, CDC7, CDK8, CHEK1, CSF1R, CSNK1A1, CSNK1D, CSNK1G1, CSNK1G2, CSNK1G3, CSNK2A1, DAPK3, DYRK1A, DYRK1B, DYRK4, EEF2K, EGFR, EPHA2, ERBB2, ERBB4, FER, FYN, GRK5, HCK, IKBKE, IRAK1, JAK3, KIT, LIMK1, MAP2K1, MAP2K2, MAP4K2, MAPK12, MAPK13, MAPK14, MAPK8, MAPK9, MAPKAPK2, MAPKAPK5, NEK2, NEK4, PAK1, PDGFRA, PDGFRB, PDK1, PDPK1, PHKG2, PIM1, PIM2, PIM3, PKD2, PRKCD, PRKCG, PRKCI, PRKCZ, PRKD2, PRKD3, PRKG1, PRKG2, ROCK1, ROCK2, RPS6KA5, RPS6KB1, SGK2, SRMS, SRPK1, STK17A, SYK, TBK1, TNK2, TSSK1B, TSSK2, TYRO3
10
(confirmed non-binding)
(Click to show)

Datasets:

HMS Dataset ID Dataset Title HMS Dataset Type
20000
Target Affinity Spectrum (TAS) vectors for compounds in the HMS LINCS small molecule library.
Analysis
20237
LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 1 of 15: Cell count and relative growth within biological replicate 1.
Microscopy/Imaging
20238
LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 2 of 15: Cell count and relative growth within biological replicate 2.
Microscopy/Imaging
20239
LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 3 of 15: Cell count and relative growth within biological replicate 3.
Microscopy/Imaging
20240
LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 4 of 15: Mean cell count and mean growth rate across biological replicate 1.
Microscopy/Imaging
20241
LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 5 of 15: Mean cell count and mean growth rate across biological replicate 2.
Microscopy/Imaging
20242
LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 6 of 15: Mean cell count and mean growth rate across biological replicate 3.
Microscopy/Imaging
20243
LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 7 of 15: Mean cell count and mean growth rate across all replicates.
Microscopy/Imaging
20245
LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 8 of 15: Cell count and normalized growth rate inhibition values within biological replicate 1.
Microscopy/Imaging
20246
LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 9 of 15: Cell count and normalized growth rate inhibition values within biological replicate 2.
Microscopy/Imaging
20247
LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 10 of 15: Cell count and normalized growth rate inhibition values within biological replicate 3.
Microscopy/Imaging
20248
LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 11 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 1.
Microscopy/Imaging
20249
LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 12 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 2.
Microscopy/Imaging
20250
LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 13 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 3.
Microscopy/Imaging
20251
LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 14 of 15: Mean cell count and mean normalized growth rate inhibition values across all replicates.
Microscopy/Imaging
20252
LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 15 of 15: Calculated dose-response metrics.
Analysis
20272
Viability and apoptosis measured by imaging in BRAF(V600E/D) melanoma cell lines following treatment with combinations of two compounds (viability/apoptosis dataset 1 of 2)
Microscopy/Imaging
20273
Viability and apoptosis measured by imaging in BRAF(V600E/D) melanoma cell lines following treatment with combinations of three compounds (viability/apoptosis dataset 2 of 2)
Microscopy/Imaging
20274
Phosphorylation state and protein levels measured by imaging in BRAF(V600E/D) melanoma cell lines following treatment with combinations of two compounds (immunofluorescence dataset 1 of 4)
Microscopy/Imaging
20275
Phosphorylation state and protein levels measured by imaging in BRAF(V600E/D) melanoma cell lines following treatment with combinations of two compounds (immunofluorescence dataset 2 of 4)
Microscopy/Imaging

Batch Information:

HMS LINCS Batch ID Provider Provider Batch ID
10072-101-1 Haoyuan chemexpress HY-999-20110107
10072-101-2 Selleck Chemicals